Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Exclusive Article Wall Street Loves FIGS. So Why Do Price Targets Predict a Pullback?Reported by Jennifer Woods. Published: 3/2/2026. After a stunning plunge following its 2021 IPO, medical and lifestyle apparel company FIGS, Inc. (NYSE: FIGS) has climbed back to a price it hasn't seen in nearly four years. The stock has surged almost 260% over the past year, including a 58% rise in the last month alone. The rally has been fueled by strong earnings reports and a wave of bullish analyst commentary. Yet despite the momentum and optimistic coverage, the consensus 12-month price target sits at just $12.25 — almost 30% below the current stock price. That raises the question: how much of this recovery is supported by fundamentals, and how much is momentum? A closer look at FIGS' recent results and the stock's price action offers some clues. Early investors in FIGS saw a quick windfall after the company's IPO, which debuted in May 2021 at $22 per share and surged to $50 within a month. Demand for medical apparel was elevated during the COVID-19 pandemic, but as the pandemic eased, shares sharply reversed course and, within 12 months, fell below $8. In the years that followed, FIGS remained mostly range-bound in the single digits. After dipping below $4 in April 2025, the stock began another climb — this time to the upside. Earnings Momentum Sparks Rally Following steady gains after positive Q1 and Q2 2025 earnings reports, the Q3 2025 results, released on Nov. 6, pushed the stock higher. The report showed stronger-than-expected revenue growth, solid demand across FIGS' core business, and resilient margins despite tariff pressures. The company also issued an upbeat outlook, raising its full-year guidance for net revenue and adjusted EBITDA margins. Wall Street reacted positively, sending the stock up more than 30% over the following week and prompting Zacks Research to upgrade the shares to Strong Buy from Hold. What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO. Click here to get the details and I'll show you how to claim your stake… Key Points - FIGS stock is up nearly 260% over the last year
- Strong earnings have fueled the rally
- Stock is trading almost 30% above the average price target
- Special Report: [Sponsorship-Ad-6-Format3]
The momentum continued after the Q4 2025 earnings report released on Feb. 26. The quarter featured a 33% jump in revenue and marked the company's best quarterly sales, topping $200 million. On the earnings call, management — which notably outfitted Team USA's medical team during the Winter Olympics — pointed to broad-based strength, including growth in active customers and higher average order values. Scrubwear — its core business, accounting for more than three-quarters of net revenue — rose 35%, and international sales climbed 55%. The fourth quarter capped a strong year for FIGS, with net revenue up 14% year-over-year to a record $630 million. Despite tariff-related pressure on gross margins, profitability held up: full-year adjusted EBITDA margin exceeded the company's target by more than 200 basis points. Earnings and Outlook Fuel Analyst Support FIGS also issued an optimistic outlook for the year ahead, expecting continued demand supported in part by growth in healthcare employment. The company plans to expand into new international markets, prioritize growth opportunities across its businesses, and continue its stock buyback program. For fiscal 2026, FIGS expects net revenue to grow 10% to 12%, with improvements in profitability targets. Analysts reacted with a flurry of upgrades and target increases after the results. Barclays raised its rating to Strong Buy from Hold; KeyCorp moved to Overweight from Sector Weight with a $17 price target; Goldman Sachs adjusted its rating to Hold from Strong Sell; BTIG reiterated its Buy rating with a $15 price target; and Telsey Advisory raised its target to $15 from $9. FIGS Stock Pushes Past Price Targets FIGS' stronger earnings have clearly driven the stock to four-year highs. Shares began rising even before the Q4 report, jumping nearly 14% in the session ahead of the release, and the rally accelerated after the results. The stock surged 24% on the first trading day following the report and added another 10% the next day. As of March 4, the stock was trading above $17, roughly 30% above the average 12-month price target of $12.25 based on 10 analyst reports. That level is more than double Morgan Stanley's $8 target issued in January and sits above the highest analyst target of $17 set by KeyCorp. The gap between upbeat analyst commentary and relatively modest price targets suggests analysts appreciate FIGS' improving fundamentals but remain cautious about valuation. At its current price, the shares trade at a price-to-earnings (P/E) ratio near 90, implying that much of FIGS' expected growth may already be priced in. Investors have applauded the turnaround, but skepticism persists about whether the stock can extend these gains or if a pullback may be likely.
| 
